Studysummary This review examines the mechanisms of Janus kinase inhibitors in treating alopecia areata and evaluates their efficacy and safety, but reports no new clinical results.
Read the full study on frontiersin.org →
Research cited in this study 48
- Global Burden of Alopecia Areata and Associated Diseases: A Trend Analysis From 1990 to 2021 PubMed · 2025
- Oral Abrocitinib for Treatment of Refractory Alopecia Areata: A Retrospective Study Journal of the American Academy of Dermatology · 2024
- Sustained Hair Regrowth With Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Trial Journal of the American Academy of Dermatology · 2024
- Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata Journal of the American Academy of Dermatology · 2024
- Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials Journal of the American Academy of Dermatology · 2024
- Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
- Nanostructured Lipid Carriers Promote Percutaneous Absorption and Hair Follicle Targeting of Tofacitinib for Treating Alopecia Areata Journal of Controlled Release · 2024
- Deciphering the Complex Immunopathogenesis of Alopecia Areata International Journal of Molecular Sciences · 2024
- Comparative Efficacy of Oral Janus Kinase Inhibitors and Biologics in Adult Alopecia Areata: A Systematic Review and Bayesian Network Meta-Analysis Journal of the European Academy of Dermatology and Venereology · 2024
- European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2024
- Gut Microbiome, Metabolome and Alopecia Areata Frontiers in microbiology · 2023
- Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program SKIN The Journal of Cutaneous Medicine · 2023
- Drug Survival and Long-Term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study Acta dermato-venereologica · 2023
- Ritlecitinib: First Approval Drugs · 2023
- Baricitinib: A Review in Severe Alopecia Areata American Journal of Clinical Dermatology · 2023
- Baricitinib for the Treatment of Alopecia Areata Drugs · 2023
- Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
- Treatment of Moderate-to-Severe Alopecia Areata in Pre-Adolescent Children with Baricitinib British Journal of Dermatology · 2023
- Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2023
- Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population JAMA Dermatology · 2023
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
- Treatment of Alopecia Areata With the Janus Kinase Inhibitor Upadacitinib: A Retrospective Cohort Study Journal of the American Academy of Dermatology · 2023
- Treatment of Moderate-to-Severe Alopecia Areata in Adolescents With Baricitinib: A Retrospective Review of 29 Patients Journal of The American Academy of Dermatology · 2023
- Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2022
- Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials British journal of dermatology/British journal of dermatology, Supplement · 2022
- A Case of Atopic Dermatitis with Alopecia Universalis in a Patient Treated with Abrocitinib JAAD case reports · 2022
- Tofacitinib as a Pragmatic Treatment Choice for Alopecia Areata: A Retrospective Review Dermatologic Therapy · 2022
- Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial Journal of the American Academy of Dermatology · 2021
- Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology · 2021
- Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
- Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata JCI insight · 2021
- A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
- The Effect of JAK Inhibitor on Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells International Journal of Molecular Sciences · 2020
- Frontiers in Alopecia Areata Pathobiology Research The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology · 2019
- Reactivation of Alopecia Areata After Dupilumab Therapy for Atopic Dermatitis Dermatitis · 2019
- Tofacitinib Therapy for Children with Severe Alopecia Areata Journal of the American Academy of Dermatology · 2019
- JAK Inhibitors and Alopecia Areata Lancet · 2019
- Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
- Ruxolitinib for the Treatment of Severe Alopecia Areata Journal of the American Academy of Dermatology · 2018
- Tofacitinib for the Treatment of Alopecia Areata in Preadolescent Children Journal of the American Academy of Dermatology · 2018
- Alopecia Areata: A Review of Disease Pathogenesis British journal of dermatology/British journal of dermatology, Supplement · 2018
- Topical 2% Tofacitinib for Children with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Journal of the American Academy of Dermatology · 2018
- Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series Journal of the American Academy of Dermatology · 2017
- Two Cases of Alopecia Areata Treated with Ruxolitinib: A Discussion of Ideal Dosing and Laboratory Monitoring International Journal of Dermatology · 2017
- Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents Journal of the American Academy of Dermatology · 2016
- Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
- Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
- Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014